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Role of cytokines in the response to erythropoietin in hemodial-
ysis patients.
Background. Cytokines are regulatory factors of erythropoiesis,
especially in pathologic conditions. Even though a relevant role
for a deranged cytokine production in the pathogenesis of dialysis
anemia has been suggested, no data are available that analyze the
role of cytokines in the key therapeutic issue of the needs of
erythropoietin. The aim of the present study in hemodialysis
patients was, therefore, to examine the relationship between the
dose of recombinant human erythropoietin (EPO) and the pro-
duction of cytokines by peripheral blood mononuclear cells
(PBMC).
Methods. After the exclusion of subjects with major active
causes of EPO resistance, data from 34 hemodialysis patients
were available for analysis. Cytokine levels were measured in the
supernatants of stimulated [with bacterial lipopolysaccharide and
interferon gamma (IFN-g)] and unstimulated PBMC. Mean
yearly values of hematocrit, hemoglobin, transferrin saturation,
ferritin, parathormone (PTH) and aluminum levels and EPO
doses (U/kg/week) were calculated. For analysis, the 34 patients
were divided according to their cutoff requirements for EPO:
patients with requirements of EPO $ 60 U/kg/week (group A1, 26
subjects) versus EPO , 60 U/kg/week (group B1, 8 subjects) and
patients with requirements of EPO $100 U/kg/week (group A2,
18 subjects) versus ,100 U/kg/week (group B2, 16 subjects).
Results. A significant direct correlation between interleukin-6
(IL-6) and tumor necrosis factor alpha (TNF-a) production values
and EPO doses was found (P 5 0.039 and P 5 0.02 respectively).
On the other hand, there was a significantly negative correlation
between interleukin-12 (IL-12) production values and EPO doses
(P 5 0.029). Patients of groups A1 and A 2 had spontaneously
higher tumor necrosis factor-a (TNF-a) and lower IL-12 and
IFNg production compared to patients from groups B1 and B2.
Conclusions. Our data disclose a previously undescribed pattern
of cytokine alteration that is relevant to determine increased
needs of EPO in hemodialysis patients. The present results have
potential applicability in designing strategies to improve EPO
resistance.
In the last decade, the use of recombinant human
erythropoietin (EPO) has revolutionized the treatment of
anemia in patients with chronic renal failure [1]. However,
in spite of this frank improvement, many uremic patients
still present a degree of resistance to the effect of EPO.
This resistance makes necessary, in many cases, the use of
high doses to reach a satisfactory level of plasma hemoglo-
bin. EPO resistance is a major issue in terms of dialysis
economy [2–4]. Some patients have EPO resistance as a
result of comorbid conditions, such as the depletion of iron
stores [5], severe hyperparathyroidism [6] or aluminum
overload [7]. However, uremia and the dialytic treatment
are by themselves important individual causes of EPO
resistance.
Hemopoiesis is a complex, multiregulated process that
requires the interaction of several factors to operate ade-
quately. The interactions are, however, still incompletely
clarified. In this regard, several cytokine molecules have
been related to the regulation of hemopoiesis in normal
individuals [8, 9]. Overt or unrecognized infection or
inflammation is a further common cause of hyporespon-
siveness to EPO, because there is an increased production
of cytokines such as tumor necrosis factor-a (TNF-a),
interleukin (IL)-1 and interferon-g (IFN-g), which might
suppress erythrocyte stem-cell proliferation [10, 11]. Fur-
thermore, alterations in the immune system are well rec-
ognized complications of chronic renal failure that are not
corrected but rather worsened by chronic maintenance
dialysis [12]. Therefore, hemodialysis treatment can poten-
tially induce further alterations in cytokine production. In
this regard, the presence of increased IL-1, IL-6 and TNF-a
levels has been reported in relation to chronic renal failure
and dialysis [13–16]; however, it is unclear whether alter-
ations in these cytokines are actually related to the EPO
responsiveness in dialysis patients. The data on this subject
are limited, but a recent study by MacDougall has sug-
gested that interleukin-3 and insulin-like growth factor-1
can potentiate erythropoiesis [17].
Recently, it has been shown that IL-12 has a direct
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enhancing effect on in vitro erythropoiesis [18, 19]. Recent
data from our laboratory have identified alterations in
IL-12 production in hemodialysis patients, which consist of
baseline increased production values at, but an absence of
stimulation by treatment with LPS/IFN-g [20]. No data are
available on IL-12 in the hemodialysis population to assess
whether this cytokine might be involved in the pathogenesis
of anemia. Based on this previous information, the aim of
the present study was to examine the alterations in cytokine
production that may contribute to a diminished response to
EPO in a group of patients on regular hemodialysis.
METHODS
Thirty-four patients with end-stage renal disease (ESRD;
22 males and 12 females, 64.0 6 10.4 years) who were
undergoing regular hemodialysis therapy were studied. All
patients were dialyzed in a University Hospital or in an
external dialysis facility depending upon the hospital. The
34 patients were randomly chosen from a total of 108
individuals dialyzed in the two Units. The patients who
presented with major comorbid conditions, namely, active
infections, inflammatory, hematologic or neoplastic dis-
ease, as well as the patients with aluminum levels higher
than 60 mg/liter or with gastrointestinal bleeding, were
excluded prior to the study. Additional exclusion criteria
based on the variability of EPO doses and blood transfu-
sions are detailed below. As an additional restrictive crite-
rium, no patient was included who presented recent (within
the last two months) major changes (63000 U/week or
more with respect to the mean yearly dose) in EPO
requirements, to avoid any bias in the results due to acute
conditions. In the same regard, no patient requiring more
than two blood transfusions during the follow-up time was
considered in the results. Eleven patients were diagnosed
with glomerulonephritis, six had nephroangiosclerosis, six
had diabetic nephropathy, three had interstitial nephropa-
thy, there were two polycystic renal disease patients, and six
had a nephropathy of unknown origin. The patients were
dialyzed for 210 to 270 minutes, three times a week, with
cuprophan (29 subjects) and polysulfone (5 subjects), non-
reused dialyzers, using bicarbonate dialysate and a blood
flow between 250 to 350 ml/min. KT/V was calculated with
the formula 2Ln(R 2 0.03 2 0.75 3 UF/W), where R is
the post/pre-urea ratio, UF is ultrafiltrate volume, and W is
postdialysis weight. All KT/V values were equal or higher
than 1.0 (Table 1). None of the patients had significant
markers of malnutrition, and the mean albumin levels were
3.9 6 0.25. All the patients studied had been on hemodi-
alysis for at least six months before being included in the
study. The production by peripheral blood mononuclear
cells (PBMC) of IL-6, IL-10, IL-12, TNF-a and IFN-g were
measured in all patients before a mid-week dialysis session.
Hematocrit (Hct), hemoglobin (Hgb), ferritin and trans-
ferrin saturation were measured once or twice a month in
hemodialysis patients during a one year period. Parathor-
mone (PTH) was determined every six months and serum
aluminum was measured yearly. The mean values of these
parameters throughout the last year were used for calcula-
tions. The mean doses of EPO received by the patients
during the same period were calculated and expressed as
U/kg/week. In all the patients, EPO was administered by
the subcutaneous route, with an initial dose of 2000 U
post-hemodialysis. The EPO dose was adjusted in an
attempt to maintain target Hct and Hgb values between 30
to 35% and 10 to 11.5 g/dl, respectively. The mean number
of blood transfusions was of 0.6 6 0.1 per year.
For the determination of cytokines, two blood samples
were drawn before the start of the dialysis procedure: 20 ml
heparinized and 10 ml clotted blood. The sera obtained
from the clotted samples were kept at 220°C until process-
ing. PBMC were obtained from the blood by density
gradient centrifugation (SEROMED; Biochrom KG, Ber-
lin, Germany). PBMC were cultured at a density of 2 3 106
cells/ml in 2 ml, 12-well microplates (Costar Corp., Cam-
bridge, MA, USA) at 37°C and 5% CO2 under the follow-
ing conditions: (1) cultured in medium only (RPMI 1640
with the suitable supplements) for 48 hours; (2) stimulated
with bacterial lipopolysaccharide (LPS 10 mg/ml; Sigma
Chemical Co., St. Louis, MO, USA) in culture medium
during 48 hours; (3) stimulated with IFN-g 100 ng/ml
(Promega Corp., Madison, WI, USA) in culture medium
during 16 hours, followed by LPS (10 mg/ml) until complet-
ing 48 hours. At the end of the culture, the cell free
supernatant was filtered, aliquoted and frozen at 270°C
Table 1. Biochemical parameters and dialysis kinetics of groups A1 (N 5 26), B1 (N 5 8), A2 (N 5 18) and B2 (N 5 16)
Group A1 Group B1 P Group A2 Group B2 P
Hct % 31.1 6 1.9 35 6 2.5 0.00004 30.8 6 2.1 33.4 6 2.5 0.002
Hgb g/dl 10 6 0.6 11.3 6 1.2 0.028 9.9 6 0.7 10.8 6 1.0 0.004
Ferritin mg/liter 311 6 156 132 6 88 0.0045 346 6 159 177 6 144 0.001
Transferrin saturation % 19 6 5.7 13 6 4.5 0.015 19.5 6 5.0 15.0 6 5.9 0.047
PTH pg/ml 247 6 225 326 6 391 NS 255 6 216 290 6 338 NS
Aluminum mg/liter 32 6 14 19 6 8 NS 31 6 15 22 6 10 NS
KT/V 1.19 6 0.1 1.17 6 0.2 NS 1.18 6 0.3 1.18 6 0.3 NS
PCR g/kg/day 0.96 6 0.3 0.88 6 0.2 NS 0.9 6 0.3 0.9 6 0.2 NS
Albumin g/dl 3.9 6 0.2 3.8 6 0.3 NS 3.9 6 0.3 3.9 6 0.2 NS
For groups A1 and B1 the cutoff erythropoietin dose was 60 U/kd/week; for groups A2 and B2 the cutoff for the dose of erythropoietin was 100
U/kg/week. Abbreviations are: Hct, hematocrit; Hgb, hemoglobin; PTH, parathormone; KT/V, dialysis dose; PCR, protein catabolism rate.
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until processing. IL-6, IL-10, TNF-a and IFNg were ana-
lyzed in these supernatants by commercially available
ELISA tests (all from Medgenix Diagnostics, Fleurus,
Belgium). In addition, to specifically detect the het-
erodimeric IL-12, an ELISA test was performed as previ-
ously described [21], with reagents kindly provided by Dr.
M.K. Gately (Hoffman-La Roche Inc., Nutley, NJ, USA).
Hematocrit and hemoglobin were determined by stan-
dard techniques (Coulter), transferrin saturation, ferritin
and PTH (intact molecule) by radioimmunoassay (Allegro
Nichols Institute, San Juan Capistrano, CA, USA), and
serum aluminum by atomic absorption spectrometry in a
graphite furnace, all as previously described [22]. The
nutritional status was evaluated by serum albumin (g/dl)
and protein catabolism rate (PCR; g/kg/day) values.
To evaluate the role of cytokines in the dialysis-associ-
ated anemia, we divided the patients in groups based on
their requirements of EPO. Accordingly, the data were
distributed on the basis of two cutoff points, namely, 60
U/kg/week and 100 U/kg/week of EPO dose. These cutoff
points yielded a distribution of the patients into four
groups: group A1 (26 subjects, EPO $ 60 U/kg/week) was
compared to group B2 (8 subjects, EPO , 60 U/kg/week),
and group A2 (18 subjects, EPO $ 100 U/kg/week) was
compared to group B2 (16 subjects, EPO , 100 U/kg/
week). It should be noted that this type of grouping
involving the same 34 individuals with two different cutoffs
necessarily implies the superposition of data from some
individuals in a continuum. For example, the group of ,100
U/kg/week included all the patients receiving ,60 U/kg/
week, but also some of those receiving $ 60 U/kg/week,
namely, those between 60 and 99 U/kg/week. Only one
patient of each group was receiving angiotensin I convert-
ing enzyme inhibitors.
Statistical analysis
The Kolmogorov-Smirnov test was used to examine the
normality of distribution of each population of results. The
unpaired Student’s t-test was used to compare the mean
values in the groups. Two quantitative variables were
compared by linear regression. Further assessment of the
relationship between cytokines and EPO requirements was
made using multiple regression analysis (R-Sigma Statisti-
cal Package, Madrid, Spain). The values are expressed as
mean 6 SD. A P value of less than 0.05 was considered
significant.
RESULTS
Significant differences in the baseline production of
several cytokines were detected at the two cutoff levels
used to analyze the results (Table 2). The patients who
required higher EPO doses (groups A1 and A2) had lower
spontaneous production of IL-12 and IFN-g and higher
spontaneous TNF-a production values than the patients
who needed less EPO (group B1 and B2; P 5 0.029 and
0.047 for IL-12, P 5 0.035 and 0.045 for IFN-g, and P 5
0.029 and 0.023 for TNF-a, respectively; Fig. 1). In addi-
tion, the patients with TNF-a $2 ng/ml (mean plus 1 SD)
and IL-6 levels $40 ng/ml, required a significantly higher
EPO dose (128 6 54 U/kg/week) than the remaining
patients with lower TNF-a and IL-6 (57 U/kg/week; P 5
0.0024; Fig. 2). These differences were not significant in
conditions of stimulation of the cytokines by LPS and
IFN-g (P NS between groups), with the exception of
LPS-stimulated TNF-a production between groups A2 and
B2 (Table 1). No differences were found in the IL-10 levels
between both groups (Table 2).
There was a significantly positive correlation between
IL-6 and TNF-a production values and EPO doses in
hemodialysis patients (r 5 0.384, P 5 0.039 for IL-6, r 5
0.379, P 5 0.02 for TNF-a; Figs. 3 and 4). On the other
hand, an inverse correlation was found between IL-12
production values and EPO doses (r 5 20.378, P 5 0.029;
Fig. 5). Furthermore, IFN-g production values reached a
nearly significant inverse correlation with respect to EPO
doses (r 5 20.322, P 5 0.058).








(N 5 16) P
IL-12 pg/ml 2.6 6 1.9 4.6 6 2.4 0.029 2.3 6 1.8 3.8 6 2.4 0.047
IL-12/LPS 2.9 6 2.6 3.5 6 1.9 NS 2.7 6 2.2 3.5 6 2.7 NS
IL-12/LPS/IFN-g 4.2 6 3.5 3.6 6 3.2 NS 4.3 6 4.0 3.8 6 2.6 NS
IL-6 (ng/ml) 55.4 6 26 38.5 6 21 NS 56.7 6 24 44.5 6 27 NS
IL-6/LPS 157 6 90 118 6 67 NS 148 6 82 147 6 95 NS
IL-6/lPS/IFN-g 140 6 89 110 6 83 NS 135 6 85 131 6 93 NS
IL-10 ng/ml 386 6 272 359 6 202 NS 425 6 296 325 6 188 NS
IL-10/LPS 1437 6 313 1463 6 395 NS 1462 6 312 1422 6 357 NS
IL-10/LPS/IFN-g 1139 6 498 1174 6 534 NS 1128 6 538 1172 6 465 NS
TNF-a ng/ml 1.9 6 0.8 1.1 6 0.4 0.029 2.0 6 0.6 1.4 6 0.8 0.023
TNF-a/LPS 5.1 6 2.8 3.9 6 3.3 NS 5.7 6 2.9 3.8 6 2.6 0.042
TNF-a/LPS/IFN-g 17.1 6 10.4 17.9 6 14.2 NS 18.0 6 10.0 17.0 6 11.0 NS
IFN-g U/ml 0.8 6 0.2 1.05 6 0.2 0.035 0.8 6 0.2 1.0 6 0.2 0.045
IFN-g/LPS 0.7 6 0.2 0.8 6 0.5 NS 0.8 6 0.5 0.8 6 0.5 NS
The group A1 and B1 cutoff point of erythropoietin dose was 60 U/kg/week; the cutoff point of erythropoietin dose was 100 U/kg/week for groups
A2 and B2.
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Multiple regression analysis was used to further explore
the relationship between cytokines and EPO doses. The
results indicate that TNF-a and IFN-g are significant
individual predictors of EPO requirements in hemodialysis
patients (correlation coefficients of 0.541 for TNF-a and
20.408 for IFN-g, P 5 0.006 and 0.019, respectively).
In spite of the higher EPO requirements, Hct and Hgb
values were significantly lower and ferritin and transferrin
saturation values higher in the patients with high EPO
requirements (Table 1). No differences were found in PTH
and serum aluminum values between both groups of hemo-
dialysis subjects.
In an attempt to identify a role of the different dialysis
membranes used, we found that IL-6 levels were signifi-
cantly higher in the patients treated with cuprophan dia-
lyzers than the patients dialyzed with polysulfone (55.2 6
26.7 vs. 37 6 9.6, P 5 0.014). However, we did not detect an
influence of the type of membrane on IL-10, IL-12, TNF-a
and IFN-g secretion by PBMC (Table 3). Mean EPO doses
were not statistically different between patients dialyzed
Fig. 1. (A) Interleukin-12 (IL-12) production by peripheral blood mono-
nuclear cells (PBMC) in groups A1, A2, B1 and B2. The cutoff was 60
U/kg/week for groups A1 and B1, and the cutoff was 100 U/kg/week for
groups A2 and B2. (B) Interferon gamma (IFN-g) production by PBMC in
groups A1, A2, B1 and B2. The cutoff was 60 U/kg/week for groups A1 and
B1, and the cutoff was 100 U/kg/week for groups A2 and B2. (C) Tumor
necrosis factor alpha (TNF-a) production by PBMC in groups A1, A2, B1
and B2. The cutoff was 60 U/kg/week for groups A1 and B1, and the cutoff
was 100 U/kg/week for groups A2 and B2. Symbols are: (u) group A; (f)
group B.
Fig. 2. Human recombinant erythropoietin (EPO) requirements in the
group of patients with tumor necrosis factor-a (TNF-a) < 2 and
interleukin-6 (IL-6) production < 40 (N 5 11; u) versus the group of
patients with TNF-a > 2 ng/ml and IL-6 production > 40 ng/ml (N 5 14;
f).
Fig. 3. Relationship between interleukin-6 (IL-6) production by periph-
eral blood mononuclear cells (PBMC) and erythropoietin (EPO) require-
ments in 34 hemodialysis subjects (r 5 0.384, P 5 0.039).
Goicoechea et al: Cytokines and dialysis anemia1340
with cuprophan versus dialyzed with polysulfone; however,
there was a tendency using less EPO in the polysulfone
treated subjects (Table 3). Finally, a positive correlation
was found between spontaneous IL-6 secretion and IL-10
and TNF-a release by PBMC in the hemodialysis patients
(r 5 0.622, P 5 0.00018 and r 5 0.567, P 5 0.001,
respectively).
DISCUSSION
The present series of results provides new information
linking EPO responsiveness to cytokine production in
patients on hemodialysis. Occult infection, as well as in-
flammatory disorders and malignant neoplastic diseases
can decrease the response to EPO [23]. An increased
production of cytokines seems to be involved in the patho-
genesis of this impaired responsiveness and a suppressor
effect on erythropoiesis of TNF-a, IFN-g [8, 24, 25] and
IL-1 [26] has been demonstrated. However, only a few
studies are available that analyze the reduced response to
EPO in hemodialysis patients from the cytokine perspec-
tive [1]. Recently, MacDougall et al proved that IL-6 lowers
the response to EPO in rabbits with chronic renal failure
and suggested a possible role of IL-6 in both erythropoiesis
and the response to EPO [27]. However, more data are
needed to convey the relationship between cytokines and
anemia in dialysis patients from a hypothetical to an
evidence-based stage.
The picture that emerges from our findings, although
rather complex, can be schematized according to simpler
guidelines. However, due to the complexity of the potential
mechanistic interactions, it is out of the scope of the
present investigation to determine which of the altered
factors identified in our study is of more importance than
the others in the EPO resistance mechanism. Moreover,
since the present study is clinically based on samples
obtained from dialysis patients, as yet we have no means to
identify the specific signaling pathways involved in the
observed effects.
Our results are potentially useful to identify the molec-
ular basis of EPO resistance. New and key findings are that
the patients needing more EPO for maintaining an accept-
able level of hemoglobin and hematocrit had a decreased
production of both IL-12 and IFN-g. Our data reveal an
inverse relationship between these cytokines and EPO
requirements. In contrast to our findings, it has been shown
that IFN-g may have a suppressor effect on erythropoiesis
[8, 24, 25], but not all studies agree on this point [26] and
the discrepancies on this issue remain to be explained. No
data have been published to date about IL-12 secretion in
the dialysis population. At the present time, IL-12 is
becoming considered a relevant component of the hemo-
poietic response. Dybedad, Larsen and Jacobsen have
recently reported that IL-12 is a potent stimulatory growth
factor for murine erythroid bone marrow progenitor cells
[18]. The finding of the absence of stimulation of IFN-g in
dialysis patients by LPS and of IL-12 by the association of
IFN-g and LPS [20] might be meaningful in terms of
stimulation of hemopoiesis. In fact, as we have recently
shown, this association is fully effective in stimulating IL-12
production in normal controls [20]. There is a short-loop,
co-stimulatory interaction between IL-12 and IFN-g [19,
28–30] that might help to explain in part the smaller
production values of IFN-g formed in the dialysis patients
and the discrepancy with the studies that demostrated a
suppressor effect of IFN-g on erythropoiesis (Fig. 6, sche-
matic view). The consequences of the lack of IL-12 stimu-
lation probably goes further than the decreased response to
EPO and might involve other aspects of the TH1 lympho-
cyte-related response [31]; however, more experiments are
needed for the identification of these other putative path-
ways.
The data obtained after stimulation with LPS and IFN-
g/LPS demonstrated that, with the exception of IL-12 and
Fig. 4. Relationship between tumor necrosis factor-a (TNF-a) produc-
tion by peripheral blood mononuclear cells (PBMC) and erythropoietin
(EPO) requirements in 34 hemodialysis subjects (r 5 0.379, P 5 0.02).
Fig. 5. Relationship between interleukin (IL)-12 production by periph-
eral blood mononuclear cells (PBMC) and erythropoietin (EPO) require-
ments in 34 hemodialysis subjects (r 5 0.378, P 5 0.029).
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IFN-g, the PBMC of the dialysis patients have a preserved
cytokine production in the face of a high degree of baseline
stimulation. In this regard, the fact that the differences
between the groups A1 and B1 and A2 and B2 were no
longer evident after the in vitro stimulation of PBMC was
not a surprising finding, provided the strong type of stim-
ulation used.
As mentioned above, we have also identified an in-
creased PBMC production of TNF-a and IL-6 in the
patients with a decreased response to EPO. Increased
baseline TNF-a production values were observed in our
hemodialysis patients [20], which suggest the existence of a
sustained degree of stimulation of inflammatory cytokines
in this population, in the absence of major infections or
inflammatory diseases. The direct correlation between IL-6
and TNF-a and EPO doses found in hemodialysis patients
is in agreement with the fact that these cytokines are
capable of interfering with normal erythropoiesis [9, 32]. In
this regard, Rosenlo¨f et al [33] reported that the resistance
to parenteral iron with no increase in the hemoglobin level
may be partly explained by disturbances in iron distribution
seen in chronic inflammation, which are related to high
concentrations of TNF-a and IL-1. Barany et al recently
stated a similar interpretation, although it is based on
indirect data and not on actual cytokine measurements
[34]. Our present data demonstrate that an interference
with normal erythropoiesis was associated to the inflamma-
tory cytokines but, as judged from the iron kinetics data, it
was most probably related to a direct effect of IL-6/TNF-a
on the erythrocyte maturation process itself, rather than
the induction of alterations in iron availability. In the same
regard, other factors, for example, serum aluminum or
PTH concentration, were not apparently involved in the
lower response to EPO in the patients of groups A1 and
A2. The lower ferritin and transferrrin saturation in the
groups with lower requirements might be interpreted as
either a manifestation of increased iron utilization due to
the more efficient erythropoiesis, or that patients with
relative EPO resistance might have received more transfu-
sions over the time. Although no differences were observed
in the number of transfusions between both groups in the
one year period of this study, the existence of differences in
the transfusional history prior to the study year cannot be
ruled out.
The effects of dialyzer membranes on cytokine activation
in hemodialyzed patients are controversial. Some studies
showed a direct relationship between cuprophan mem-
branes and an increase in plasma levels of IL-1, IL-6 and
TNF-a, but others did not find any difference between
cellulosic and polyacrylonitrile or polysulfone membranes
[12, 35]. Our data show a significantly higher IL-6 produc-
tion by PBMC in patients dialyzed with cuprophan mem-
branes with respect to the patients dialyzed with polysul-
fone. Also, the tendency to use less EPO was observed in
the polysulfone treated patients. However, the interpreta-
tion of our data regarding membrane-related differences is
hampered by the marked differences in the number of
individuals dialyzed with each type of membrane, which can
generate a statistical bias. In addition, since our samples for
cytokine production were taken before the beginning of a
hemodialysis session, the possibility exists that dialysis and
membrane-related effects may have became less apparent
throughout the interdialytic period. Therefore, the results
regarding the differences due to dialyzer biocompatibility
need to be reassessed in larger groups of patients using
each type of membrane, and analyzing samples taken at
different times from the end of the dialysis session to the
beginning of the next hemodialysis session.
In conclusion, our study discloses a network of possible
interactions between cytokines that lead to increased re-
quirements for EPO in dialysis patients. A schematic
interpretative view of the principle of these interactions is
shown in Figure 6. Our results provide a database that
might be useful in the development of new strategies to
improve EPO resistance.
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APPENDIX
Abbreviations used in this article are: EPO, erythropoietin; ESRD,
end-stage renal disease; Hct, hematocrit; Hgb, hemoglobin; IFN-g, inter-
feron-g; IL, interleukin; LPS, lipopolysaccharide; KT/V, dialysis dose;
PBMC, peripheral blood mononuclear cells; PCR, protein catabolism
rate; PTH, parathormone; TNF-a, tumor necrosis factor-a.
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